Breaking News, Collaborations & Alliances

POINT Biopharma, AdvanCell Partner to Develop Lead-212-Labeled Radioligand

Collaboration enables both the development and scaled commercialization of ²¹²Pb-labeled radioligand therapies.

POINT Biopharma Global Inc., a company developing radiopharmaceuticals, and AdvanCell, a company developing an innovative pipeline of targeted alpha therapies with a platform technology to produce 212Pb radiopharmaceuticals, entered into a collaboration on the development of a global 212Pb radioisotope and radiolig and supply chain and drug manufacturing network to specifically support the clinical development and commercialization of 212Pb-labeled radioligands by each company. 212Pb is diffe...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters